Inventiva Stock

Inventiva EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Inventiva (IVA.PA) as of Aug 17, 2026 is -7.99. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -11.17 — a change of -28.44% (higher).

EV/EBIT

-7.99

YoY

-28.44%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Inventiva is 2026 -7.99 . EV/EBIT (Enterprise Value to EBIT) of Inventiva was 2025 -11.17 . It decreases by -28.44% higher compared to the previous year.

The Inventiva EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.24 base
Jan 1, 2020
-15.11 base
Jan 1, 2021
-8.92 base
Jan 1, 2022
-3.29 base
Jan 1, 2023
-1.89 base
Jan 1, 2024
-1.51 base
Jan 1, 2025
-5.41 base
Jan 1, 2026 (e)
-126.92 base
YEARPRICE-TO-EBIT
2026 est -126.92
2025 -5.41
2024 -1.51
2023 -1.89
2022 -3.29
2021 -8.92
2020 -15.11
2019 -3.24
2018 -1.87
2017 -1.93
2016 -
2015 -
2014 -
2013 -
Access this data via the Eulerpool API

Inventiva Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Inventiva's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Inventiva's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Inventiva's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Inventiva grows earnings faster than its peers.

Inventiva Stock analysis

What does Inventiva do? Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva stock

EV/EBIT (Enterprise Value to EBIT) of Inventiva is -7.99 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Inventiva changed from -11.17 to -7.99, representing a -28.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Inventiva since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Inventiva with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Inventiva

All Key Metrics — Inventiva